- Home
- PAVM vs SNTI Comparison
PAVM vs SNTI Comparison
Compare PAVM & SNTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PAVM
- SNTI
- Stock Information
- Founded
- PAVM 2014
- SNTI 2016
- Country
- PAVM United States
- SNTI United States
- Employees
- PAVM N/A
- SNTI N/A
- Industry
- PAVM Medical/Dental Instruments
- SNTI Biotechnology: Pharmaceutical Preparations
- Sector
- PAVM Health Care
- SNTI Health Care
- Exchange
- PAVM Nasdaq
- SNTI Nasdaq
- Market Cap
- PAVM 10.2M
- SNTI 10.4M
- IPO Year
- PAVM 2016
- SNTI N/A
- Fundamental
- Price
- PAVM $1.01
- SNTI $2.13
- Analyst Decision
- PAVM Strong Buy
- SNTI
- Analyst Count
- PAVM 1
- SNTI 0
- Target Price
- PAVM $21.00
- SNTI N/A
- AVG Volume (30 Days)
- PAVM 52.5K
- SNTI 17.0K
- Earning Date
- PAVM 11-13-2024
- SNTI 11-14-2024
- Dividend Yield
- PAVM N/A
- SNTI N/A
- EPS Growth
- PAVM N/A
- SNTI N/A
- EPS
- PAVM 0.53
- SNTI N/A
- Revenue
- PAVM $4,034,000.00
- SNTI N/A
- Revenue This Year
- PAVM $70.80
- SNTI $254.47
- Revenue Next Year
- PAVM $298.02
- SNTI $169.66
- P/E Ratio
- PAVM $1.95
- SNTI N/A
- Revenue Growth
- PAVM 166.27
- SNTI N/A
- 52 Week Low
- PAVM $0.60
- SNTI $1.52
- 52 Week High
- PAVM $4.88
- SNTI $7.43
- Technical
- Relative Strength Index (RSI)
- PAVM 43.42
- SNTI 44.88
- Support Level
- PAVM $0.99
- SNTI $2.08
- Resistance Level
- PAVM $1.10
- SNTI $2.30
- Average True Range (ATR)
- PAVM 0.09
- SNTI 0.18
- MACD
- PAVM -0.00
- SNTI -0.00
- Stochastic Oscillator
- PAVM 9.09
- SNTI 12.82
About PAVM PAVmed Inc.
PAVmed Inc is a multi-product, commercial-stage medical technology company organized to advance a broad pipeline of medical technologies from concept to commercialization. The Company operates in a single segment as a medical technology company, with the following lines of business: Diagnostics, Medical Devices, and Digital Health. Its products are EsoGuard, esocheck, and the Veris Cancer Care Platform.
About SNTI Senti Biosciences Inc.
Senti Biosciences Inc is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with their gene circuit platform technologies to fight challenging diseases. The product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma.